Effect of P-Glycoprotein Modulator, Cyclosporin A, on the Gastrointestinal Excretion of Irinotecan and Its Metabolite SN-38 in Rats
- 1 January 2003
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 20 (6) , 910-917
- https://doi.org/10.1023/a:1023847521767
Abstract
Purpose. The purpose of this work was to investigate the role of the hepatic and intestinal P-glycoprotein (P-gp) and canalicular multispecific organic anion transporter /multidrug resistance-associated protein 2 (cMOAT/MRP2) on both biliary excretion and intestinal exsorption of irinotecan hydrochloride (CPT-11) and its metabolite, SN-38, in the lactone and carboxylate forms. Cyclosporin A (CsA) was used to modulate P-gp and cMOAT/MRP2. Methods. The transcellular transport of CPT-11 and SN-38 was examined by using LLC-PK1 derivative cell lines transfected with murine mdr1a both in the absence or in the presence of CsA. The excretions of the compounds through the biliary and intestinal membrane routes were investigated by in situ perfusion technique. Results. Basolateral-to-apical transport of CPT-11 lactone in L-mdr1a cells was significantly decreased by CsA (10 μM). The trans- cellular transport of SN-38 lactone showed similar behaviors as those of CPT-11 lactone. The biliary excretion and the intestinal exsorption of both forms of CPT-11 and SN-38 were significantly inhibited when the drug was co-administered with CsA. Conclusions. The transports of CPT-11 and SN-38 via the biliary route seem to be essentially related with cMOAT/MRP2, whereas those of both compounds via the intestinal membrane seem to be related with P-gp.Keywords
This publication has 24 references indexed in Scilit:
- The Potential for an Interaction between MRP2 (ABCC2) and Various Therapeutic Agents: Probenecid as a Candidate Inhibitor of the Biliary Excretion of Irinotecan MetabolitesDrug Metabolism and Pharmacokinetics, 2002
- Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).2001
- Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.Cancer Chemotherapy and Pharmacology, 1998
- Drug exsorption from blood into the gastrointestinal tract.Pharmaceutical Research, 1998
- Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.1997
- MDR1 substrates/modulators protect against beta-estradiol-17beta-D-glucuronide cholestasis in rat liver.1996
- Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.1996
- Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1994
- Cytogenetic Effects of CPT-11 and Its Active Metabolite, SN-38 on Human LymphocytesJapanese Journal of Clinical Oncology, 1993
- Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.Proceedings of the National Academy of Sciences, 1987